Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 1Dwarfism, Pituitary 1Diabetes Mellitus, Type 2 1

Interventions

Educational Status 5Interviews as Topic 4Methods 3Magnetic Resonance Imaging 3Early Intervention, Educational 3Cisplatin 3Blood Specimen Collection 3pembrolizumab 2Surveys and Questionnaires 2Standard of Care 2Nivolumab 2Music Therapy 2Gemcitabine 2Counseling 2zilucoplan 1tislelizumab 1somapacitan 1sacituzumab govitecan 1rozanolixizumab 1oxycodone-acetaminophen 1ibrutinib 1futibatinib 1fluorodopa F 18 1erdafitinib 1enzalutamide 1enfortumab vedotin 1dynorphin-converting endopeptidase 1durvalumab 1dalpiciclib 1brexucabtagene autoleucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × somapacitan × 90 days × Clear all
NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Novo Nordisk A/S

Enrolling by invitation
500 enrolled
Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡